Landos Biopharma Inc. (LABP)
NASDAQ: LABP
· Real-Time Price · USD
22.93
0.13 (0.57%)
At close: May 23, 2024, 10:00 PM
Landos Biopharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | -18M | -18M | n/a | n/a | 18M | 18M | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | 224K | 224K | 224K | 224K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | -224K | -224K | -18.22M | -18.22M | n/a | n/a | 18M | 18M | n/a |
Operating Income | -25.24M | -22.43M | -22.63M | -25.26M | -32.09M | -40.56M | -54.44M | -59.02M | -43.87M | -38.82M | -29.82M | -25.84M | -34.81M |
Interest Income | 401K | 449K | 449K | 449K | 449K | n/a | 320K | 320K | 499K | 499K | 179K | 284K | 241K |
Pretax Income | -24.8M | -21.93M | -21.05M | -23.08M | -30.45M | -39.28M | -54.14M | -58.85M | -43.47M | -38.42M | -29.67M | -25.29M | -34.17M |
Net Income | -24.8M | -21.49M | -19.25M | -21.35M | -28.73M | -37.92M | -54.14M | -58.78M | -43.38M | -38.42M | -29.67M | -25.29M | -34.17M |
Selling & General & Admin | 13.42M | 10.43M | 10.36M | 11.2M | 13.88M | 14.88M | 18.73M | 18.83M | 16.76M | 15.25M | 9.74M | 8.13M | 6.9M |
Research & Development | 11.82M | 12M | 12.27M | 14.06M | 18.21M | 25.68M | 35.71M | 40.19M | 45.11M | 41.56M | 38.08M | 35.7M | 27.9M |
Other Expenses | n/a | n/a | n/a | -67K | -110K | -22K | -22K | 45K | 129K | 105K | 105K | 105K | 64K |
Operating Expenses | 25.24M | 22.43M | 22.63M | 25.26M | 32.09M | 40.56M | 54.44M | 59.02M | 61.87M | 56.82M | 47.82M | 43.84M | 34.81M |
Interest Expense | 1.1M | 1.1M | 557K | 624K | 67K | 67K | 387K | 511K | 511K | 511K | 191K | n/a | n/a |
Selling & Marketing Expenses | -300K | -300K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 25.24M | 22.43M | 22.63M | 25.26M | 32.09M | 40.56M | 54.44M | 59.02M | 61.87M | 56.82M | 47.82M | 43.84M | 34.81M |
Income Tax Expense | n/a | -445K | -1.8M | -1.73M | -1.71M | -1.36M | -4K | -71K | -89K | 64K | 64K | 64K | 64K |
Shares Outstanding (Basic) | 6.21M | 6.21M | 6.21M | 6.21M | 6.48M | 4.03M | 4.03M | 4.03M | 4.03M | 4.02M | 4M | 3.36M | 2.61M |
Shares Outstanding (Diluted) | 6.21M | 6.21M | 6.21M | 6.21M | 6.48M | 4.03M | 4.03M | 4.03M | 4.03M | 4.02M | 4M | 3.44M | 2.61M |
EPS (Basic) | -3.99 | -3.42 | -3.39 | -4.43 | -6.61 | -9.42 | -13.66 | -14.88 | -10.87 | -11 | -8.7 | -8.02 | -10.68 |
EPS (Diluted) | -3.99 | -3.42 | -3.39 | -4.43 | -6.61 | -9.42 | -13.66 | -14.88 | -10.87 | -11 | -8.7 | -8.02 | -10.68 |
EBITDA | -25.2M | -22.38M | -22.59M | -25.22M | -31.88M | -40.01M | -53.82M | -58.34M | -43.34M | -38.53M | -29.56M | -25.67M | -34.83M |
EBIT | -24.75M | -21.93M | -24.6M | -25.91M | -33.86M | -42.24M | -53.78M | -58.36M | -43.17M | -38.21M | -29.77M | -25.78M | -29.66M |
Depreciation & Amortization | 55.69K | 16.41K | -576.59K | -509.92K | -350.92K | -2.92K | 633.08K | 654K | 505K | 196K | 176K | 164K | 151K |